Hester Biosciences Quarterly Results for Trading Insights
In Mar 2026, Hester Biosciences (HESTERBIO) reported revenue ₹102 Cr and net profit ₹17 Cr — revenue +34.2% YoY. Analyse HESTERBIO promoter holding to track promoter, FII and institutional holdings.
HESTERBIO Quarterly Results — Revenue, Profit & EPS Highlights
Hester Biosciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Hester Biosciences stock price NSE.
- Revenue of ₹102 Cr in Mar 2026 (-38.6% vs Jun 2026, +34.2% vs Mar 2025)
- Net Profit of ₹17 Cr in Mar 2026 (-82.5% vs Jun 2026, +750.0% vs Mar 2025)
- EBITDA of ₹36 Cr in Mar 2026 (-67.9% vs Jun 2026)
- Operating Margin of 34.0% in Mar 2026 (+5.0pp vs Jun 2026)
- Earnings Per Share of ₹19.45 in Mar 2026 (-82.9% vs Jun 2026)
Hester Biosciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
HESTERBIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 102 | 166 | 83 | 76 | 88 | -38.6% | 34.2% |
| Net Profit (₹ Cr) | 17 | 97 | 14 | 2 | 17 | - | - |
| EBITDA (₹ Cr) | 36 | 112 | 24 | 14 | 26 | - | - |
| EPS (₹) | 19.45 | 113.71 | 16.85 | 1.82 | 20.33 | - | - |
| Operating Margin (%) | 34.0% | 29.0% | 17.0% | 23.0% | 27.0% | - | - |
HESTERBIO Share Price Trend — 1-Year Movement Across Quarterly Results
Hester Biosciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View HESTERBIO 52-week high low for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
HESTERBIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Hester Biosciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores